New Issue: UBS sells $894,000 trigger autocallable contingent yield notes add-on on pharma stocks

By William Gullotti

Buffalo, N.Y., Aug. 10 – UBS AG, London Branch sold an additional $894,000 of trigger autocallable contingent yield notes with memory interest due May 22, 2025 linked to the least performing of the common stocks of AbbVie Inc., Abbott Laboratories, Johnson & Johnson and Merck & Co., Inc., according to a 424B2 filing with the Securities and Exchange Commission.

Each month, the notes will pay a coupon at the rate of 12% per year if each stock closes at or above its coupon barrier, 80% of its initial level, on any related observation date. Any unpaid coupons will also be paid.

The notes will be automatically called at par plus coupon if the shares of each stock close at or above its initial share price on any quarterly call observation date.

If the notes are not called and the final share price of each stock is greater than or equal to the downside threshold level, 70% of the initial share price, the payout at maturity will be par. Otherwise, investors will receive shares of the least performing stock.

UBS Securities LLC and UBS Investment Bank are the agents.

Issuer:	UBS AG, London Branch
Issue:	Trigger autocallable contingent yield notes with memory interest
Underlying stocks:	AbbVie Inc., Abbott Laboratories, Johnson & Johnson, Merck & Co., Inc.
Amount:	$894,000, add-on
Maturity:	May 22, 2025
Coupon:	12% per year, paid monthly, if each stock closes at or above its coupon barrier on any related observation date; previously unpaid coupons will also be paid
Price:	Par
Payout at maturity:	Par unless any stock finishes below downside threshold level, in which case investors will receive shares of the least performing stock
Call:	Automatically at par plus coupon if each stock closes at or above initial level on any quarterly call observation date
Initial levels:	$116.89 for AbbVie, $116.74 for Abbott, $170.39 for J&J, $79.87 for Merck
Coupon barrier levels:	$93.51 for AbbVie, $93.39 for Abbott, $136.31 for J&J, $63.90 for Merck; 80% of initial levels
Downside thresholds:	$81.82 for AbbVie, $81.72 for Abbott, $119.27 for J&J, $55.91 for Merck; 70% of initial levels
Share amount per note:	8.5551 for AbbVie, 8.566 for Abbott, 5.8689 for J&J, 12.5203 for Merck
Pricing date:	May 17
Settlement date:	May 20
Agents:	UBS Securities LLC and UBS Investment Bank
Fees:	1.25%
Cusip:	90276BJ38

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.